A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent

Trial Profile

A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Cilengitide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2010 Actual end date (December 2007) added as reported by ClinicalTrials.gov.
    • 05 Nov 2010 Actual end date (December 2007) added as reported by ClinicalTrials.gov.
    • 05 Nov 2010 Actual end date (December 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top